Sol-Gel Technologies - SLGL Company Short-Term Debt

Combating dermatological pathologies requires minimizing side effects, which makes the historical short-term debt data on the GURU.Markets chart significant, where the parameter value equals 0.00. Sol-Gel Technologies (SLGL) addresses this through silica microencapsulation, which provides pricing power. The licensing model for proprietary developments allows for the scaling of royalties, creating powerful operating leverage and protecting business margins.

For Sol-Gel Technologies (SLGL), managing current liabilities is critical when scaling the production of proprietary drug delivery systems in dermatology. By analyzing the level of short-term debt load, an investor assesses the aggregate of payments maturing within one year, which allows for the determination of the cost of capital's sensitivity to interest rates and the risk of liquidity shortages when financing working capital.